Onconetix, Inc.ONCO
Price (close)
$0.91
Market cap
$3.6M
P/E
—
Revenue (TTM)
$645,824
Net income
-$10.2M
Dividend yield
—
1-year total return
-99.4%
Net margin
-1578.8%
Revenue growth
-51.3%
Debt / equity
—
What Onconetix, Inc. does.
focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. Through our
acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally
developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (“IVDR”), which
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $58,465 | $2.5M | $815,371 |
| Net income | — | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| Free cash flow | — | -$2.0M | -$8.7M | -$13.6M | -$10.5M | — |
More on ONCO.
- Onconetix, Inc. summary
- Onconetix, Inc. financial statements
- Onconetix, Inc. key metrics
- Onconetix, Inc. health scores and style box
- Onconetix, Inc. earnings
- Onconetix, Inc. dividends
- Onconetix, Inc. valuation
- Onconetix, Inc. ownership and insiders
- Onconetix, Inc. peers
Figures from Onconetix, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.